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Objective: Henoch-Schönlein purpura (HSP) is the most common vasculitis in children 
but it is not exceptional in adults. Increased familial occurrence supports a genetic 
predisposition for HSP. In this context, an association with the human leukocyte 
antigen-HLA-DRB1*01 phenotype has been suggested in Caucasian individuals with 
HSP. However, data on the potential association of HSP with HLA-DRB1*01 were based 
on small case series. To further investigate this issue, we performed HLA-DRB1 
genotyping of the largest series of HSP patients ever assessed for genetic studies in 
Caucasians. 
Methods: 342 Spanish patients diagnosed with HSP fulfilling the American College of 
Rheumatology and the Michel et al classification criteria, and 303 sex and ethnically 
matched controls were assessed. HLA-DRB1 alleles were determined using a PCR–
Sequence-Specific-Oligonucleotide Probe (PCR-SSOP) method. 
Results: A statistically significant increase of HLA-DRB1*01 in HSP patients when 
compared with controls was found (43% vs 7%, respectively; p<0.001; odds ratio-
OR=2.03 [1.43-2.87]). It was due to the increased frequency of HLA-DRB1*0103 
phenotype in HSP (14% vs 2%; p<0.001; OR=8.27 [3.46-23.9]). These results remained 
statistically significant after adjusting for Bonferroni correction. In contrast, a 
statistically significant decreased frequency of the HLA-DRB1*0301 phenotype was 
observed in patients compared to controls (5.6% vs 18.1%, respectively; p<0.001, 
OR=0.26 [0.14-0.47]), even after adjustment for Bonferroni correction. No HLA-DRB1 
association with specific features of the disease was found. 
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Conclusion: Our study confirms an association of HSP with HLA-DRB1*01 in 
Caucasians. Also, a protective effect against the development of HSP appears to exist 
in Caucasians carrying the HLA-DRB1*03 phenotype. 
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Henoch-Schönlein purpura (HSP), recently renamed immunoglobulin A (IgA) vasculitis, 
is the most common type of primary small-sized blood vessel leukocytoclastic vasculitis 
in children but it is not exceptional in adults (1). The classic clinical triad of HSP consists 
of palpable purpura, involving predominantly the lower extremities, joint and 
gastrointestinal manifestations. However, renal complications may also be observed in 
patients with this condition (2, 3). In this regard, the outcome of patients with HSP is 
linked to the presence of glomerulonephritis that in some cases, mainly in adults, may 
lead to chronic renal failure.  
The etiology of HSP remains unknown, although some pieces of evidence support 
immunopathological mechanisms (3). Besides environmental and socioeconomical 
factors, a genetic preposition to HSP is suggested by both familial case clusters and 
immunogenetic studies (3). In this respect, it is plausible to think that, as with many 
other immune-mediated disorders, the genetic basis of susceptibility to HSP may be 
conferred by different genes, including those located in the human leukocyte antigen 
(HLA) region. 
HLA region includes a group of genes located in chromosome 6 (6p21) that encodes 
the most polymorphic human proteins, the class I and class II antigen-presenting 
molecules (4). HLA is involved not only in the immune response against infectious 
pathogens, but also in the response against self-antigens. Accordingly, HLA is the main 
genetic factor implicated in inflammatory immune-mediated pathologies, being 
associated with more diseases than any other region of the human genome (4). In this 
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way, a few studies performed in HSP patients suggest a potential association between 
HLA genes class II region and this pathology in Caucasian individuals (5, 6). However, 
these studies were performed in small series of HSP patients that were generally 
assessed in tertiary referral centers.  
Taken together these considerations, we aimed to establish whether the HLA-DRB1   
locus is actually involved in the susceptibility to HSP in the largest series of Caucasian 
patients with this vasculitis ever assessed for genetic studies. 
 
Patients and Methods 
Patients and Study Protocol 
A set of 342 Spanish patients with cutaneous vasculitis who fulfilled Michel et al. (7) 
classification criteria for HSP were included in the present study. According to these 
criteria, they were classified as having HSP if they fulfilled 3 or more of the following 
characteristics: palpable purpura, bowel angina, gastrointestinal bleeding, macroscopic 
or microscopic hematuria, age at disease onset ≤ 20 years, and no previous history of 
medications prior to the onset of the disease. Also, all patients included in this series 
were required to fulfill the American College of Rheumatology classification criteria for 
HSP (8). Blood samples were obtained from patients recruited from Hospital 
Universitario Lucus Augusti (Lugo), Hospital Universitario Marqués de Valdecilla 
(Santander), Hospital Universitario La Princesa (Madrid), Hospital Universitario San 
Cecilio (Granada), Hospital Universitario Virgen del Rocío (Sevilla) and Hospital 
Universitario de Basurto (Bilbao). Information on the main features of the whole series 
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of 342 HSP Spanish patients recruited in this study is shown in Table 1. Clinical 
definitions of HSP features were reported elsewhere (2, 5). Hematuria with or without 
proteinuria and severe gastrointestinal manifestations were frequently observed in 
these patients. However, only 24 of the 342 patients (7%) had persistent renal 
involvement (renal sequelae) at last follow-up. 
A set of 303, sex and ethnically matched controls without history of cutaneous 
vasculitis or any other autoimmune disease constituted by blood donors from National 
DNA Bank Repository (Salamanca, Spain), was also included in the study.  
A subject’s written consent was obtained according to the declaration of Helsinki, and 
the study was approved by the Ethics Committees of Galicia for Hospital Universitario 
Lucus Augusti, of Cantabria for Hospital Universitario Marqués de Valdecilla, of Madrid 
for Hospital Universitario La Princesa, of Andalucía for Hospital Universitario San 
Cecilio and Hospital Universitario Virgen del Rocío, and of País Vasco for Hospital 
Universitario de Basurto. 
 
Genotyping 
High-molecular-weight genomic deoxyribonucleic acid (DNA) was extracted from 
whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. 
All DNA samples were stored at -20ºC until the HLA analysis. DNA-based HLA class II 
typing was performed by PCR–Sequence-Specific Oligonucleotide Probe (PCR-SSOP) 
using the Luminex 100 system (Luminex, Austin, TX, USA) and the Lifecodes HLA typing 
Kits (Gen-Probe Inc., San Diego, CA, USA) following the manufacturer’s instructions. 
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Negative and positive controls and duplicate samples were included to check the 
accuracy of genotyping. 
 
Statistical analysis 
Continuous data were described as mean and standard deviation (mean ± SD) and 
categorical variables as percentages. 
The strength of association between HSP and HLA-DRB1 phenotypes was estimated 
using odds ratios (OR) and 95% confidence intervals (CI). Levels of significance were 
determined using contingency tables by either chi-square test or Fisher exact 
(expected values below 5) analysis. Results were adjusted for Bonferroni correction.   
In order to obtain an internal validation of the associations that had never been 
reported before, we carried out a bootstrap test with 1000 replications. 
All analyses were performed with STATA statistical software 12/SE (Stata Corp., College 
Station, TX, USA). 
 
Results 
Table 2 describes the HLA-DRB1 phenotype frequencies in the whole cohort of HSP 
patients and controls.  
When HSP patients were compared with matched controls, some differences in HLA-
DRB1 phenotype frequencies were observed. In this regard, in keeping with data 
previously reported in small series of Caucasian individuals with HSP (5, 6), HLA-
DRB1*01 phenotype was significantly increased in HSP patients compared to controls 
(43% versus 27%, respectively; p<0.001; OR=2.03 [1.43-2.87]). This association is 
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mainly due to HLA-DRB1*0103 allele (14% in HSP patients versus 2% in controls; 
p<0.001; OR=8.27 [3.46-23.9]) (Table 2). These results remained statistically significant 
after adjusting for Bonferroni correction. In contrast, a statistically significant decrease 
in the frequency of the HLA-DRB1*03 phenotype, due to the presence of HLA-
DRB1*0301 allele, was observed in HSP patients compared to controls (5.6% versus 
18.1%, respectively; p<0.001, OR=0.26 [0.14-0.47]) (Table 2). These results remained 
statistically significant after adjusting for Bonferroni correction. Since information on 
the potential protective effect of HLA-DRB1*03 on HSP had not been previously 
reported, we carried out a bootstrapping procedure that confirmed the protective 
effect on HSP susceptibility associated with HLA-DRB1*03 (OR=0.22; 95% CI: 0.13- 
0.40). However, no statistically significant results were observed regarding other HLA-
DRB1 phenotypes and HSP susceptibility (Table 2). 
No HLA-DRB1 phenotype differences were observed when patients were stratified 
according to specific features of the disease, such as age at onset before and after 20 
years, presence of joint or gastrointestinal manifestations. It was also the case when 
HSP patients who experienced nephritis or had renal sequelae at last follow-up were 




The vasculitides constitute a heterogeneous group of diseases characterized by a 
primary process of inflammation and damage of the blood vessel wall (9). These 
disorders often have overlapping clinical and pathological manifestations (9). A 
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number of studies have highlighted the relevant role of a genetic component in the 
susceptibility and severity of these conditions, being HLA the main genetic factor 
related to these pathologies. However, there is scarce information on the implication 
of HLA genes in HSP. In fact, only a few studies performed in small cohorts of patients 
have been carried out to evaluate the potential association between HLA class II genes 
and HSP (5, 6). Because of that, we have performed a study to establish whether the 
HLA-DRB1 gene is actually involved in the susceptibility to HSP in the largest series of 
Caucasian patients with this vasculitis ever assessed for genetic studies. In this context, 
our findings support the role of the HLA-DRB1*01 phenotype in HSP as a susceptibility 
marker of this disease (5, 6). Additionally, we also observed a protective effect against 
the development of HSP in individuals carrying the HLA-DRB1*03 phenotype which 
was overall less frequently observed compared to the HLA-DRB1*01 phenotype in both 
HSP patients and controls. 
HLA-class II molecules have been associated with different types of primary systemic 
vasculitis. With respect to this, an association of HLA-DRB1*04 with giant cell arteritis, 
a large-sized blood vessel vasculitis, has been observed (10).  An intergenic region 
between HLA-DQB2 and HLA-DOB was associated with Kawasaki disease, a vasculitis 
involving medium-sized blood vessels (11). Additionally, HLA-DP and HLA-DRB1*04 has 
been shown to be related to small-sized vessel anti-neutrophil cytoplasmic antibody 
(ANCA)-associated vasculitides, which includes granulomatosis with polyangiitis, 
microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (12). 
Furthermore, HLA-DQw7, HLA-DRB1*03, HLA-DRB1*01, HLA-DRB1*09 and HLA-
DRB1*04 have also been involved in the susceptibility to granulomatosis with 
polyangiitis (13). 
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Frequent overlap between vasculitides, mainly in those involving the skin blood 
vessels, often occurs. It is especially true in cases of adults with small vessel vasculitis 
presenting with palpable purpura. In this regard, in a former study of our group we 
suggested that, unlike HSP patients, those with isolated cutaneous leukocytoclastic 
vasculitis are not associated with any specific HLA-DRB1 pattern of disease 
susceptibility. However, that study was based on a small series of cases (14). 
Interestingly, Cacoub et al reported an influence of HLA-DRB1 locus on the risk of 
hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) (15). Like HSP, MC is 
often associated with small-sized blood vessel vasculitis, and palpable purpura is also a 
typical presenting feature of the cryoglobulinemic vasculitis. These authors found that 
HLA-DRB1*11 was significantly more frequent in patients with type II MC than in those 
without MC, regardless of the presence of vasculitis accompanying the MC. In contrast, 
HLA-DRB1*07 was less frequent in HCV-infected patients with MC than in those 
without MC, with a particularly lower frequency in those with type II vasculitis.  
Although in the present study we also found the association with HLA-DRB1*01 shown 
in previous reports and, because of that, it may be considered in itself as a 
confirmatory study, there are a number of potential limitations that need to be 
addressed. First, we observed a protective effect against HSP susceptibility mediated 
by HLA-DRB1*03.  This result needs to be confirmed using an independent cohort of 
Caucasian individuals with HSP. Moreover, an analysis focused on the potential 
implication of HLA-class I molecules is also warranted to elucidate the implication of 
HLA region in the susceptibility to HSP. 
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In conclusion, our study supports an association of HSP with HLA-DRB1. These results 
may have clinical implication as they may help to better identify patients with this 
vasculitis.    
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Table 1. Main features of a series of 342 Spanish patients with HSP. 
Main characteristics % (n/N) 
Children (age ≤20 years)/ adults (age >20 years) 279/63 
Male/ female 176/165 
Age at the onset of the disease (years)  
         mean ± SD 14.7 ± 17.8 
         median [IQR] 7 [5-16] 
Duration of follow-up (years, mean ± SD) 2.4 ± 1.7 
Palpable purpura and/or maculopapular rash 100 (342/342) 
Arthralgia and/or arthritis 56.7 (194/342) 
Gastrointestinal manifestations (if “a” and/or “b”) 53.5 (183/342) 
       a) Bowel angina 52.0 (178/342) 
       b) Gastrointestinal bleeding 15.7 (54/342) 
Renal manifestations (if any of the following characteristics) 35.3 (121/342) 
       a) Hematuria 34.5 (118/342) 
       b) Proteinuria 32.7 (112/342) 
       c) Nephrotic syndrome 3.5 (12/342) 
       d) Renal sequelae (persistent renal involvement)* 7.0 (24/342) 
HSP: Henoch-Schönlein purpura; SD: standard deviation; IQR: Interquartile Range. 
*At last follow-up. 
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Table 2. HLA-DRB1 phenotype frequencies in patients with HSP and controls. 
HLA-DRB1 Patients with HSP (n=342) Controls (n=303) P OR [95% CI] 
DRB1*01 0101 66 (19.3) 40 (13.2) 0.037 1.57 [1.00-2.47] 
0102 32 (9.3) 36 (12.2) 0.29 0.76 [0.45-1.30] 
0103 49 (14.3) 6 (1.9) <0.001 8.27 [3.46-23.9]  
DRB1*03 0301 19 (5.6) 55 (18.1) <0.001 0.26 [0.14-0.47] 
DRB1*04 0401 18 (5.2) 10 (3.3) 0.22 1.63 [0.69-4.01] 
 0402 7 (2.0) 4 (1.3) 0.47 1.56 [0.39-7.34] 
 0403 24 (7.0) 19 (6.3) 0.70 1.13 [0.58-2.23] 
 0404 15 (4.4) 18 (5.9) 0.37 0.73 [0.33-1.56] 
 0405 20 (5.8) 16 (5.3) 0.75 1.11 [0.54-2.34] 
 0407 7 (2.04) 2 (0.7) 0.13 3.14 [0.59-31.2] 
 0408 9 (2.6) 1 (0.3) 0.02 8.16 [1.12-358.8] 
DRB1*11 1101 50 (14.6) 45 (14.8) 0.93 0.98 [0.62-1.56] 
 1102 6 (1.7) 6 (1.9) 0.83 0.88 [0.23-3.34] 
 1103 3 (0.6) 2 (0.7)  0.75 1.33 [0.15-16.0] 
 1104 9 (2.6) 7 (2.3) 0.79 1.14 [0.37-3.65] 
DRB1*12 1201 13 (3.8) 9 (2.9) 0.56 1.29 [0.50-3.47] 
DRB1*13 1301 45 (13.1) 27 (8.9) 0.09 1.55 [0.91-2.67] 
 1302 19 (5.6) 23 (7.6) 0.29 0.72 [0.36-1.40] 
 1303 8 (2.3) 11 (3.6) 0.33 0.63 [0.22-1.76] 
 1305 4 (1.2) 4 (1.3) 0.86 0.88 [0.16-4.79] 
DRB1*14 1404 7 (2.0) 15 (4.9) 0.04 0.40 [0.14-1.06] 
DRB1*07 0701 84 (24.6) 78 (25.7) 0.73 0.94 [0.64-1.36] 
DRB1*08 0801 19 (5.6) 11 (3.6) 0.25 1.56 [0.69-3.69] 
 0804 2 (0.6) 2 (0.7) 0.90 0.88 [0.06-12.28] 
DRB1*09 0901 7 (2.05) 5 (1.6) 0.71 1.24 [0.34-5.02] 
DRB1*10 10 10 (2.9) 11 (3.6) 0.61 0.80 [0.29-2.01] 
HLA: Human leukocyte phenotype; HSP: Henoch- Schönlein purpura; OR: odds ratio; CI: 
confidence interval. 
Values are expressed as n (percentages, %). The results that remained statistically significant 
after adjusting for Bonferroni correction are highlighted in bold. 
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